Litigation Details for Amgen Inc. v. MSN Laboratories Private Limited (D. Del. 2021)

Amgen Inc. v. MSN Laboratories Private Limited (D. Del. 2021)

Docket		Date Filed	2021-05-06
Court	District Court, D. Delaware	Date Terminated	2023-11-14
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Parties	AMGEN INC.
Patents	10,344,765; 11,162,500; 8,377,880; 8,999,932; 9,278,995; 9,701,712; 9,820,938
Attorneys	Cortlan S. Hitch
Firms	Morris James LLP
Link to Docket	External link to docket

Details for Amgen Inc. v. MSN Laboratories Private Limited (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-05-06				External link to document
2021-05-06	1	Complaint	expiration of U.S. Patent Nos. 9,820,938 (“the ’938 patent”) and 10,344,765 (“the ’765 patent”) (collectively… 1. This is an action for patent infringement under the patent laws of the United States, Title…for its infringement of the ’938 patent. 28. The ’765 patent, titled “Stable Liquid Formulation…the expiration of the ’938 patent is an act of infringement of the ’938 patent under 35 U.S.C. § 271(e)…Aurobindo has knowledge of the ’938 patent at least because the ’938 patent is listed in the FDA’s Orange	External link to document
2021-05-06	149	Notice of Service	Final Validity Contentions for U.S. Patent Nos. 9,820,938, 10,344,765, and 11,165,500 filed by Amgen Inc…Plaintiffs' Final Validity Contentions for U.S. Patent Nos. 8,999,932, 8,377,880, 9,278,995, and 9,701,712… 14 November 2023 1:21-cv-00662 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-05-06	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,820,938 B2; 10,344,765 B2. (kmd) (… 14 November 2023 1:21-cv-00662 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Amgen Inc. v. MSN Laboratories, 1:21-cv-00662: Litigation Summary and Patent Analysis

Last updated: August 6, 2026

Amgen v. MSN Laboratories concerns MSN’s abbreviated new drug application for generic cinacalcet hydrochloride, the active ingredient in Amgen’s Sensipar product. The case became a major Federal Circuit decision on obviousness-type double patenting, or ODP. The Federal Circuit rejected the district court’s broad ODP analysis and held that a later-issued patent is not invalid for ODP when it expires before the asserted reference patent. The decision restored Amgen’s ability to pursue infringement claims on remand, although it did not itself establish infringement or guarantee a generic launch bar.

What drug and patents are at issue in Amgen v. MSN Laboratories?

The litigation involves cinacalcet hydrochloride, marketed by Amgen as Sensipar.

Cinacalcet is a calcimimetic used primarily for:

• Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis;
• Hypercalcemia in patients with parathyroid carcinoma; and
• Severe hypercalcemia in patients with primary hyperparathyroidism who cannot undergo parathyroidectomy.

MSN filed an ANDA seeking FDA approval for generic cinacalcet hydrochloride tablets. Amgen sued under the Hatch-Waxman Act after receiving a Paragraph IV certification challenging Amgen’s listed patents.

The Federal Circuit appeal centered on Amgen’s patent family and the application of ODP. The principal patents discussed in the appellate decision were U.S. Patent Nos. 9,375,405 and 10,092,541. The patents are related to cinacalcet treatment and formulation subject matter, with overlapping disclosures and patent-term relationships.

Item	Detail
Branded product	Sensipar
Active ingredient	Cinacalcet hydrochloride
Plaintiff	Amgen Inc.
Defendant	MSN Laboratories Private Limited
Court	U.S. District Court for the District of Delaware
Civil action	1:21-cv-00662
Statutory basis	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)
Generic pathway	ANDA
Principal legal issue	Obviousness-type double patenting
Appellate court	U.S. Court of Appeals for the Federal Circuit
Federal Circuit decision	Amgen Inc. v. MSN Laboratories Private Ltd., 119 F.4th 1379 (Fed. Cir. 2024)

What was the procedural history of the case?

Amgen filed the Delaware action in 2021 after MSN submitted its ANDA for generic cinacalcet tablets. The complaint alleged that MSN’s ANDA and proposed commercial activities would infringe Amgen’s listed patents.

The district court resolved the ODP issue before a full infringement trial. It held that the asserted patent claims were invalid under ODP based on related Amgen patents. The court’s reasoning treated the later-expiring patent as an unjustified extension of the patent term associated with an earlier patent in the same family.

Amgen appealed to the Federal Circuit.

In November 2024, the Federal Circuit reversed the district court’s ODP judgment and remanded the case. The appellate court held that ODP did not invalidate the challenged patent claims merely because the patents were related and had different issuance dates. The relevant inquiry was the patents’ expiration sequence, not simply which patent issued first.

The appellate decision did not enter a final judgment that MSN infringed. It also did not determine the ultimate FDA approval date for MSN’s ANDA.

What did the Federal Circuit decide in Amgen v. MSN?

The Federal Circuit held that a patent cannot be invalidated for ODP when it expires before the patent asserted as the ODP reference.

The court’s analysis focused on the purpose of ODP. The doctrine prevents an applicant from obtaining a second patent that extends exclusivity for the same invention or an obvious variation after the first patent expires. According to the Federal Circuit, that concern does not arise when the challenged patent expires first.

The court distinguished the case from situations in which a later-issued patent obtains a longer effective term and thereby extends exclusivity beyond an earlier patent. The court also addressed its prior decision in In re Cellect, which held that patent term adjustment can create an ODP problem when the adjusted patent expires after a related patent.

The practical rule from Amgen v. MSN is:

1. Identify the patent expiration dates.
2. Determine whether the challenged patent expires later than the reference patent.
3. Apply ODP only if the challenged patent creates an unjustified extension of patent exclusivity.
4. Do not invalidate the challenged patent merely because it issued later or has a later patent number.

This ruling narrows the use of ODP as a pretrial invalidity defense in pharmaceutical patent litigation.

How does Amgen v. MSN compare with In re Cellect?

Amgen v. MSN and In re Cellect both address ODP, but the expiration-date relationship produced different outcomes.

Issue	In re Cellect	Amgen v. MSN
Central question	Whether patent term adjustment can create an ODP defect	Whether ODP applies when the challenged patent expires before the reference patent
Patent-term feature	Later patent received additional patent term adjustment	Challenged patent did not create a later expiration relative to the relevant reference patent
Federal Circuit result	ODP applied	ODP did not invalidate the challenged claims
Commercial effect	Patent term adjustment could not defeat ODP	Related patent status alone did not defeat validity
Strategic lesson	Track PTA and expiration dates across a continuation family	Compare actual expiration dates before asserting ODP

The decisions together make patent-term mapping critical. A continuation’s later issuance is not enough to establish ODP. The challenger must show a legally relevant extension of patent exclusivity.

What was the Paragraph IV challenge and generic entry risk?

MSN’s ANDA included a Paragraph IV certification challenging Amgen’s listed patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Amgen’s lawsuit triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the statutory rules governing the timing and effect of patent litigation.

The principal generic-entry scenarios were:

Scenario	Effect
Amgen obtains final infringement judgment	MSN’s approval and commercial launch could be delayed until the relevant patent barriers expire or are otherwise removed
MSN defeats infringement claims	FDA approval could proceed subject to regulatory requirements
MSN invalidates the patents on remand	The corresponding patent barriers would be removed
Settlement	Entry timing would depend on the agreement and any applicable antitrust or FTC review
No enforceable patent barrier remains	MSN could launch after FDA approval and completion of other ANDA requirements

The Federal Circuit reversal increased Amgen’s litigation leverage because the asserted patents survived the ODP ruling at that procedural stage. The decision did not eliminate MSN’s noninfringement defenses, other invalidity defenses, or regulatory hurdles.

What is the Orange Book status of Sensipar?

Sensipar was approved by the FDA as an NDA product for cinacalcet hydrochloride. The Orange Book has historically listed Amgen patents associated with Sensipar and its approved uses.

Orange Book-listed patents can support a Hatch-Waxman infringement action when an ANDA applicant makes a Paragraph IV certification. The relevant listing must correspond to the drug product, formulation, or approved method of use under FDA listing rules.

The Orange Book analysis should distinguish among:

• Product patents covering cinacalcet or its pharmaceutical composition;
• Formulation patents covering tablet composition, excipients, or release characteristics;
• Method-of-use patents covering approved cinacalcet indications; and
• Patents that may be expired, delisted, or no longer create a practical entry barrier.

The existence of an Orange Book listing does not establish infringement. The ANDA product must be compared with the asserted claims, and the court must resolve validity and enforceability defenses.

What formulation and method-of-use patents protect cinacalcet?

The Sensipar estate includes overlapping patent categories rather than a single exclusivity right.

Formulation protection

Formulation claims may cover:

• Cinacalcet hydrochloride in a tablet dosage form;
• Specific excipient combinations;
• Pharmaceutical compositions with defined concentration ranges;
• Tablet manufacturing parameters; and
• Stability or dissolution characteristics.

A generic applicant can avoid some formulation claims by using a different excipient system or manufacturing process. That strategy does not avoid method-of-use claims if the ANDA labeling still directs use for a patented indication.

Method-of-use protection

Method claims can cover treatment of:

• Secondary hyperparathyroidism;
• Hypercalcemia associated with parathyroid carcinoma; and
• Primary hyperparathyroidism in specified patient populations.

Method-of-use patents often present a narrower barrier than composition patents. A generic applicant may seek a skinny label that omits a patented indication. The legal outcome depends on the proposed label, physician prescribing behavior, induced-infringement evidence, and the precise claim language.

How strong is Amgen’s patent estate after the Federal Circuit ruling?

The Federal Circuit ruling materially improved the strength of Amgen’s position on the specific ODP issue. It did not convert the patent estate into an absolute barrier to generic entry.

Strengths

• The principal asserted claims were no longer subject to the district court’s ODP judgment.
• The Federal Circuit provided a favorable rule for patent owners with related patents that do not create a later expiration date.
• Amgen retained the ability to pursue infringement claims on remand.
• The patents were asserted against an ANDA product, creating a conventional Hatch-Waxman framework and potential stay protection.

Constraints

• The decision did not resolve infringement.
• Other invalidity defenses remained available.
• Cinacalcet is a small-molecule product, so biosimilar concepts do not apply.
• Patent-term expiration remains the controlling commercial limit.
• A generic applicant can pursue claim-by-claim noninfringement positions, including formulation or labeling differences.

The estate is therefore stronger as a litigation asset than it was after the district court’s ODP ruling, but its commercial value depends on the remaining patent terms and the outcome of remand proceedings.

Which companies are challenging Sensipar exclusivity?

MSN Laboratories is the named challenger in Civil Action No. 1:21-cv-00662. The litigation reflects broader generic competition for cinacalcet, a product whose regulatory exclusivity and core patent protection have substantially matured.

Other generic manufacturers may pursue separate ANDAs or rely on different certification strategies. Separate ANDA litigation does not automatically create estoppel against MSN unless the relevant patent, claims, facts, and procedural posture satisfy the requirements for preclusion.

The competitive landscape includes:

• Generic tablet manufacturers;
• Contract manufacturers with ANDA capabilities;
• Companies challenging formulation patents;
• Companies using skinny-label strategies for method-of-use claims; and
• Potential licensees or settlement counterparties.

No biosimilar pathway is implicated because cinacalcet is a chemically synthesized small molecule, not a biologic.

What litigation and settlement risks remain?

The Federal Circuit remanded the case after reversing the ODP ruling. The principal remaining risks were:

1. Infringement: whether MSN’s proposed product practices the asserted claims.
2. Claim construction: how the court interprets the composition, dosage, treatment, and formulation limitations.
3. Other invalidity grounds: including anticipation, obviousness, written description, enablement, and indefiniteness.
4. Induced infringement: particularly for method-of-use claims and ANDA labeling.
5. Settlement: whether the parties agree to a licensed entry date or other resolution.
6. Regulatory timing: whether FDA approval is available when the patent case no longer prevents launch.

A settlement could provide MSN with a negotiated launch date before the latest patent expiration. The commercial value of such a settlement would depend on Sensipar sales, generic price erosion, the number of approved competitors, and the scope of any licensed claims.

What is the revenue exposure from generic cinacalcet entry?

Generic entry would typically produce rapid price erosion for a small-molecule oral product. The magnitude depends on the number of entrants, channel inventory, payer substitution, authorized-generic strategy, and whether Amgen retains any enforceable formulation or method-of-use rights.

Revenue exposure is highest where:

• The generic has approval for the principal commercial indication;
• Multiple ANDA applicants enter simultaneously;
• No meaningful formulation differentiation exists;
• Payers impose automatic substitution; and
• The branded product has limited clinical switching costs.

Revenue exposure is lower where:

• Patent litigation delays approval;
• The generic label omits commercially important indications;
• Amgen maintains an authorized generic;
• Distribution contracts limit substitution; or
• The branded product retains a protected formulation or delivery attribute.

The case should be evaluated as a mature small-molecule exclusivity dispute rather than as a biologic or platform-patent case.

Key Takeaways

• Amgen v. MSN concerns MSN’s ANDA for generic cinacalcet hydrochloride.
• The district court invalidated Amgen’s asserted claims under ODP.
• The Federal Circuit reversed and remanded in 2024.
• The appellate rule requires a meaningful patent-term extension before ODP invalidity applies.
• Later issuance alone does not establish ODP.
• The ruling preserved Amgen’s infringement case but did not decide infringement or guarantee a generic launch delay.
• Paragraph IV litigation and the Hatch-Waxman 30-month stay remain central to the entry analysis.
• No biosimilar risk exists because cinacalcet is a small-molecule drug.
• The main commercial risk is rapid generic price erosion once an enforceable patent barrier and FDA approval no longer prevent entry.

FAQs About Amgen v. MSN Laboratories

What product did MSN seek to market?

MSN sought FDA approval for generic cinacalcet hydrochloride tablets, equivalent to Amgen’s Sensipar product.

Did the Federal Circuit find MSN’s generic product infringing?

No. The Federal Circuit addressed the ODP validity issue and remanded the case. It did not enter a final infringement judgment against MSN.

Does the ruling invalidate all Amgen cinacalcet patents?

No. The decision addressed the challenged claims and the ODP analysis in the case. It did not invalidate Amgen’s entire cinacalcet patent estate.

Can a generic launch before all Sensipar patents expire?

Potentially, if the generic obtains FDA approval and defeats or avoids enforceable patent claims, reaches a settlement with Amgen, or relies on a label that does not induce infringement of a valid method-of-use patent.

Is Amgen v. MSN relevant to biosimilar litigation?

No. The dispute involves cinacalcet, a chemically synthesized small molecule regulated through the ANDA pathway, not a biologic regulated through the biosimilar pathway.

References

1. Amgen Inc. v. MSN Laboratories Private Ltd., 119 F.4th 1379 (Fed. Cir. 2024).

2. Amgen Inc. v. MSN Laboratories Private Limited, No. 1:21-cv-00662, U.S. District Court for the District of Delaware.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.

4. U.S. Food and Drug Administration. (2024). Approved drug product labeling: Sensipar (cinacalcet hydrochloride).

5. In re Cellect, LLC, 81 F.4th 1216 (Fed. Cir. 2023).